+高级检索
首页 > 优先出版
PDF HTML阅读 XML下载 导出引用 引用提醒
饮食诱导非酒精性脂肪性肝病动物模型的研究进展
作者:
作者单位:

1.哈尔滨医科大学;2.大庆油田总医院;3.连云港市红十字中心血站

基金项目:

国家自然科学基金青年科学基金


Advances in animal models of diet-induced nonalcoholic fatty liver disease
Author:
Affiliation:

1.Harbin Medical University;2.Oilfields General Hospital in Daqing;3.Lianyungang city Red Cross center blood station

Fund Project:

National Natural Science Foundation Youth Science Foundation

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [36]
    • | | | |
  • 文章评论
    摘要:

    建立科学有效的动物模型是完成疾病研究的关键步骤。饮食诱导是常见的建立非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD) 疾病动物模型的方法。常见饮食诱导的NAFLD的动物模型主要包括高脂高糖饮食诱导模型、高脂高胆固醇饮食诱导模型和胆碱缺乏饮食诱导模型，由于不同造模方式其摄入的营养成分不同，使得肝脏出现脂肪性变形、炎症及纤维化等病理特征不同。此外，不同动物模型的疾病进程、疾病严重程度以及适用的研究亦各有不同。本文通过分析比较常见的不同饮食诱导NAFLD动物模型在造模方式、造模时间、病理学特征、适用研究及相关优缺点，为NAFLD研究者选择动物模型提供参考。

    Abstract:

    The establishment of scientific and effective animal models is a key step to complete disease research. Diet induction is a common method to establish animal models of nonalcoholic fatty liver disease (NAFLD). The common animal models of diet-induced NAFLD mainly include high-fat and high-sugar diet-induced model, high-fat and high-cholesterol diet-induced model, and choline-deficient diet-induced model. Due to the different nutrients ingested by different modeling methods, the pathological characteristics such as fatty deformation, inflammation and fibrosis of the liver are different. In addition, different animal models vary in disease progression, disease severity, and applicable studies. This article analyzes and compares the common animal models of NAFLD induced by different diets in modeling methods, modeling time, pathological characteristics, applicable research, and related advantages and disadvantages, so as to provide reference for NAFLD researchers to select animal models.

    参考文献
    [1] Cobbina E, Akhlaghi F. Non-Alcoholic Fatty Liver Disease (NAFLD) – Pathogenesis,Classification,and Effect on Drug Metabolizing Enzymes and Transporters[J]. Drug Metab Rev, 2017, 49(2):197-211.
    [2] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med，2018，24(7):908-922.
    [3] Kanda T, Goto T, Hirotsu Y, et al. Molecular Mechanisms:Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma[J]. Int J Mol Sci，2020，21(4):1525-1542.
    [4] Loomba R, Sanyal AJ. The global NAFLD epidemic[J]. Nat Rev Gastroenterol Hepatol，2013，10(11):686-90.
    [5] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell，2021，184(10):2537-2564.
    [6] Tetri LH，Basaranoglu M，Brunt EM，et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent [J]. Am J Physiol Gastrointest Liver Physiol, 2008, 295(5):G987-95.
    [7] Ackerman Z, Oron HM, Grozovski M, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction [J]. Hypertension, 2005, 45 (5): 1012 -1018.
    [8] Armutcu F, Coskun O, Gurel A, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats [J]. Clin Biochem, 2005, 38 (6): 540 -547.
    [9] Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice [J]. Hepatology, 2009, 50(4): 1094-1104.
    [10] Buettner R, Parhofer KG, Woenckhaus M, et al. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types [J]. J Mol Endocrinol, 2006, 36(3): 485–501.
    [11] Kohli R, Kirby M, Xanthakos SA, et al.High-Fructose Medium-Chain-Trans-Fat Diet Induces Liver Fibrosis & Elevates Plasma Coenzyme Q9 in a Novel Murine Model of Obesity and NASH [J]. Hepatology，2010，52(3):934-44.
    [12] Marí M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas- mediated steatohepatitis [J]. Cell Metab，2006，4(3):185–198.
    [13] Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis[J]. Gastroenterology，2011，141(4):1393–1403.
    [14] Caballero F, Fernández A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH[J]. J Hepatol， 2009，50（4）:789–96.
    [15] Min H- K, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease[J]. Cell Metab, 2012，15（5）:665–674.
    [16] Van Rooyen DM, Gan LT, Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome[J]. J Hepatol ，2013，59（1）:144–152.
    [17] Subramanian S, Goodspeed L, Wang S, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice [J]. J Lipid Res, 2011, 52(9): 1626 -1635.
    [18] Savard C, Tartaglione EV, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis [J]. Hepatology, 2013, 57(1): 81-92.
    [19] Ye D, Li FY, Lam KS, et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice[J]. Gut，2012，61(7):1058-67.
    [20] Miura K, Kodama Y, Inokuchi S, et al.Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice[J]. Gastroenterology，2010，139(1):323-347.
    [21] Yang L, Miura K, Zhang B, et al. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice[J]. Cell Mol Gastroenterol Hepatol, 2017, 3(3):469-483.
    [22] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis [J]. Hepatology, 2010， 52(5): 1836-1846.
    [23] Koh EH, Yoon JE, Ko MS, et al. Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non- alcoholic steatohepatitis [J]. Gut，2021，70(10):1954-1964.
    [24] Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection [J]. Hum Reprod Update, 2019, 25(6): 673-693.
    [25] Buettner R, Parhofer KG, Woenckhaus M, et al. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types [J]. J Mol Endocrinol，2006，36（3）: 485–501.
    [26] Zadelaar S, Kleemann R, Verschuren L, et al. Mouse models for atherosclerosis and pharmaceutical modi?ers [J]. Arterioscler Thromb Vasc Biol，2007，27: 1706-21.
    [27] Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right[J]. J Gastroenterol Hepatol, 2008, 23: 1635-48.
    [28] Tous M, Ferre N, Camps J, et al. Feeding apolipoprotein E-knockout mice with
    [29] cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis[J].
    [30] Mol Cell Biochem, 2005, 268: 53-8.
    [31] [29] Sahai A, Malladi P, Melin-Aldana H, et al. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model[J]. American journal of physiology Gastrointestinal and Liver Physiology, 2004, 287: G264–73.
    [32] [30] Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J]. Gastroenterology, 1996, 111:1645–53.
    [33] [31] Machado MV, Michelotti GA, Xie G, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease[J]. PLoS One, 2015 May 27; 10(5):e0127991.
    [34] [32] Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance[J]. J Hepatol, 2004, 40:47–51.
    [35] [33] Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J]. J Lipid Res. 2008 May, 49(5):1068–76.
    [36] [34] Rinella ME(1), Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet.[J]. J Mol Endocrinol，2006，36（3）: 485–501.
    相似文献
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

复制
分享
文章指标
  • 点击次数:574
  • 下载次数: 0
  • HTML阅读次数: 0
  • 引用次数: 0
历史
  • 收稿日期:2023-09-18
  • 最后修改日期:2023-11-09
  • 录用日期:2023-12-04
您是第8979496 位访问者
版权所有:中国比较医学杂志 主管单位：中国科学技术协会 主办单位：中国实验动物学会 中国医学科学院医学实验动物研究所
地址：北京市朝阳区潘家园南里5号 邮 编 ：100021 电话：010-67779337 E-mail:bjb@cnilas.org
技术支持：北京勤云科技发展有限公司
防诈骗提示！请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭